These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20598155)

  • 1. p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.
    Flak MB; Connell CM; Chelala C; Archibald K; Salako MA; Pirlo KJ; Lockley M; Wheatley SP; Balkwill FR; McNeish IA
    Mol Cancer; 2010 Jul; 9():175. PubMed ID: 20598155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
    Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
    Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.
    Lockley M; Fernandez M; Wang Y; Li NF; Conroy S; Lemoine N; McNeish I
    Cancer Res; 2006 Jan; 66(2):989-98. PubMed ID: 16424034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.
    Ingemarsdotter CK; Baird SK; Connell CM; Öberg D; Halldén G; McNeish IA
    Oncogene; 2010 Nov; 29(45):6051-63. PubMed ID: 20729921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.
    Baird SK; Aerts JL; Eddaoudi A; Lockley M; Lemoine NR; McNeish IA
    Oncogene; 2008 May; 27(22):3081-90. PubMed ID: 18071311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.
    Salako MA; Kulbe H; Ingemarsdotter CK; Pirlo KJ; Williams SL; Lockley M; Balkwill FR; McNeish IA
    Mol Ther; 2011 Mar; 19(3):490-9. PubMed ID: 21081903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
    Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
    Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
    Connell CM; Shibata A; Tookman LA; Archibald KM; Flak MB; Pirlo KJ; Lockley M; Wheatley SP; McNeish IA
    J Clin Invest; 2011 Apr; 121(4):1283-97. PubMed ID: 21383502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
    Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
    Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro.
    Shi J; Fu S; Wang L; Tao Y; Rodriguez R; Wang Z
    Anticancer Drugs; 2017 Jan; 28(1):88-96. PubMed ID: 27622605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses.
    Shiina M; Lacher MD; Christian C; Korn WM
    Cancer Gene Ther; 2009 Nov; 16(11):810-9. PubMed ID: 19407849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.
    Browne A; Tookman LA; Ingemarsdotter CK; Bouwman RD; Pirlo K; Wang Y; McNeish IA; Lockley M
    Cancer Res; 2015 Jul; 75(14):2811-21. PubMed ID: 25977332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.
    Ingemarsdotter CK; Tookman LA; Browne A; Pirlo K; Cutts R; Chelela C; Khurrum KF; Leung EY; Dowson S; Webber L; Khan I; Ennis D; Syed N; Crook TR; Brenton JD; Lockley M; McNeish IA
    Mol Oncol; 2015 Apr; 9(4):791-805. PubMed ID: 25560085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
    Bazan-Peregrino M; Carlisle RC; Hernandez-Alcoceba R; Iggo R; Homicsko K; Fisher KD; Halldén G; Mautner V; Shen Y; Seymour LW
    Hum Gene Ther; 2008 Sep; 19(9):873-86. PubMed ID: 18710328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy.
    Hoare JI; Osmani B; O'Sullivan EA; Browne A; Campbell N; Metcalf S; Nicolini F; Saxena J; Martin SA; Lockley M
    Commun Biol; 2022 Feb; 5(1):106. PubMed ID: 35115660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A.
    Savelyeva I; Dobbelstein M
    Oncogene; 2011 Feb; 30(7):865-75. PubMed ID: 20935676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.